The National Institute for Health and Care Excellence (NICE) recommends Viekirax (ombitasvir + paritaprevir + ritonavir), from AbbVie, with or...
AbbVie has announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of Viekirax (ombitasvir/paritaprevir/ritonavir...
AbbVie announced new data showing high response rates with just eight weeks of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets)...
In final guidance, NICE has recommended Viekirax (ombitasvir–paritaprevir–ritonavir) with or without Exviera (dasabuvir), from Abbvie, as a possible treatment for...
The Japanese Ministry of Health, Labour and Welfare approved AbbVie’s Viekirax (ombitasvir/paritaprevir/ritonavir), as a new interferon-free and ribavirin-free treatment option...
The German Institute for Quality and Efficiency in Health Care (IQWiG) has re-examined the added benefit of Exviera plus Viekirax...
Enanta Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
AbbVie has announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase IIIb RUBY-I study...
The European Medicines Agency (EMA) has started a review of medicines known as direct-acting antivirals used for treating chronic (long-term)...
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions...